OrbiMed

Insilico Medicine, Inc. is a biotechnology company that leverages artificial intelligence (AI) to transform drug discovery, biomarker development, and aging research. Founded in 2014 and based in Baltimore, Maryland, the company has established itself as a pioneer in applying advanced AI techniques, such as generative adversarial networks and reinforcement learning, to create novel molecular structures for various diseases, including cancer and age-related conditions. Insilico Medicine operates an integrated platform that covers all stages of drug discovery, from initial research to clinical trial analysis. Its projects include Pharma.AI, which offers machine learning services to various sectors, and Young.AI, a platform focused on aging predictors. The company also pursues internal drug discovery initiatives targeting diseases like Alzheimer's and Parkinson's, and has partnered with Life Extension to produce nutraceutical products utilizing deep learning and bioinformatics. Additionally, Insilico Medicine provides consumer applications aimed at enhancing health and longevity.

Triveni Bio is a biotechnology company specializing in the development of novel antibody therapies for immunological and inflammatory disorders. The company employs a genetics-driven precision medicine approach to identify patients most likely to respond to its treatments, aiming to accelerate drug development and improve the effectiveness and safety of therapies.

Mirador Therapeutics specializes in developing precision medicine technologies to tackle immune-mediated inflammatory and fibrotic diseases. The company's core offering is a proprietary data analytics engine that integrates comprehensive patient molecular profiles, pinpoints novel therapeutic targets, and facilitates the creation of targeted diagnostics. This enables researchers and healthcare providers to tailor treatments to individual patients' genetics, potentially enhancing outcomes for those with chronic conditions.

BiomX develops bacteriophage-based therapies targeting bacteria linked to skin conditions and chronic diseases such as inflammatory bowel disease, liver disorders, and cancer. It collaborates with renowned institutions for research and development, aiming to create innovative microbiome therapeutics.

Triveni Bio is a biotechnology company specializing in the development of novel antibody therapies for immunological and inflammatory disorders. The company employs a genetics-driven precision medicine approach to identify patients most likely to respond to its treatments, aiming to accelerate drug development and improve the effectiveness and safety of therapies.

Adela specializes in developing innovative technologies for early detection of high-morbidity conditions like cancer through routine blood tests. Its proprietary platform efficiently captures and analyzes the methylome, focusing on highly informative regions to enhance diagnostic accuracy.

BiomX develops bacteriophage-based therapies targeting bacteria linked to skin conditions and chronic diseases such as inflammatory bowel disease, liver disorders, and cancer. It collaborates with renowned institutions for research and development, aiming to create innovative microbiome therapeutics.

Delfi Diagnostics, Inc. is a biotechnology company based in Baltimore, Maryland, focused on the early detection of cancer through innovative blood tests. Founded in 2018, the company employs artificial intelligence and genome sequencing to identify unique patterns of DNA fragmentation in the blood, enabling the detection of previously unrecognized cancer-associated cell-free DNA fragments. By utilizing machine learning, Delfi Diagnostics aims to develop high-precision, non-invasive blood tests that allow healthcare professionals to detect cancer at its most curable stage, thereby facilitating timely and effective treatment options for patients.

LifeWell is a new entity formed through the merger of LifeCell’s diagnostics business and MFine.

DarioHealth is a digital health company that develops and commercializes patented and proprietary technology enabling smartphone-based laboratory testing and real-time diabetes management. Its flagship Dario system combines a mobile software application with a pocket-sized blood glucose monitoring device, backed by the DarioEngage platform that provides coaching, digital communications, alerts, trend analysis, and support for chronic illness management. The company markets its solutions directly to consumers and through retail pharmacies, hospitals, and distributors across international markets, with sales occurring online as well. DarioHealth operates at the intersection of life sciences, behavioral science, and software, delivering digital therapeutics-style interventions that are personalized and data-driven across diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health through a suite of software, devices, and coaching services. Established in 2011 and headquartered in Israel, DarioHealth focuses on transforming self-management of chronic conditions by integrating software, monitoring hardware, and remote coaching.

Founded in 2008, Nucleix Ltd. specializes in developing non-invasive molecular diagnostic tests for early cancer detection. Its proprietary tests, Bladder EpiCheck and Lung EpiCheck, identify subtle methylation changes in urine and blood samples respectively.

Humacyte specializes in developing human tissue-based products for regenerative medicine and vascular surgery. It creates acellular extracellular matrices using banked vascular smooth muscle cells, which are then decellularized to eliminate rejection risks. These matrices serve as off-the-shelf tissue-engineered grafts for patients requiring vascular repair or replacement.

Rimag is a Shenzhen‑based medical imaging service provider that operates a network of imaging centers offering MRI, CT, PET, X‑ray, ultrasound and mammography. The company also develops cloud‑based imaging solutions and provides training for medical imaging professionals. Its revenue is primarily derived from the operation of imaging centers, while additional income comes from imaging solution services and cloud services.

Adela specializes in developing innovative technologies for early detection of high-morbidity conditions like cancer through routine blood tests. Its proprietary platform efficiently captures and analyzes the methylome, focusing on highly informative regions to enhance diagnostic accuracy.

Insilico Medicine, Inc. is a biotechnology company that leverages artificial intelligence (AI) to transform drug discovery, biomarker development, and aging research. Founded in 2014 and based in Baltimore, Maryland, the company has established itself as a pioneer in applying advanced AI techniques, such as generative adversarial networks and reinforcement learning, to create novel molecular structures for various diseases, including cancer and age-related conditions. Insilico Medicine operates an integrated platform that covers all stages of drug discovery, from initial research to clinical trial analysis. Its projects include Pharma.AI, which offers machine learning services to various sectors, and Young.AI, a platform focused on aging predictors. The company also pursues internal drug discovery initiatives targeting diseases like Alzheimer's and Parkinson's, and has partnered with Life Extension to produce nutraceutical products utilizing deep learning and bioinformatics. Additionally, Insilico Medicine provides consumer applications aimed at enhancing health and longevity.

Binx Health Limited is an in vitro diagnostics company based in Trowbridge, United Kingdom, founded in 2005. The company specializes in developing diagnostic instruments and disposable cartridge systems for decentralized laboratory and point-of-care settings. Its flagship product, the binx io platform, is the first FDA-cleared, CLIA-waived system for detecting chlamydia and gonorrhea in both males and females, delivering results comparable to central laboratory performance within approximately thirty minutes. Binx Health aims to enhance healthcare access by addressing traditional barriers and extending outreach through its point-of-care diagnostic solutions. The company also focuses on providing rapid polymerase chain reaction (PCR)-based results and a comprehensive digital program that includes evidence-based testing, counseling, treatment, and follow-up services. Binx Health has established a strategic partnership with Sherlock Biosciences, further strengthening its commitment to improving community health outcomes.

Founded in 2008, Nucleix Ltd. specializes in developing non-invasive molecular diagnostic tests for early cancer detection. Its proprietary tests, Bladder EpiCheck and Lung EpiCheck, identify subtle methylation changes in urine and blood samples respectively.

Yisheng Biopharma Co., Ltd. is a biopharmaceutical company focused on the research, development, manufacturing, and marketing of immuno-oncology products and vaccines. Founded in 2002 and headquartered in Beijing, the company operates in China, the United States, Cambodia, and Singapore. Yisheng Biopharma utilizes its novel PIKA immunomodulating technology to enhance immune responses against cancers and infectious diseases. Key products under development include YS-ON-001, an investigational therapy aimed at treating advanced solid tumors, as well as YS-HBV-001, a vaccine for hepatitis B, and a PIKA-based rabies vaccine designed for rapid protection against rabies infection. The company's innovative approach targets multiple immune pathways to improve treatment outcomes.

AnchorDx is a biotechnology company specializing in next-generation sequencing techniques, particularly through the use of molecular liquid biopsies. This innovative approach allows for non-invasive access to genetic information, enabling patients to gain insights into their physiological conditions and better prepare for potential health issues. With a core team boasting over 20 years of experience in cancer genomics, genetics, and bioinformatics, AnchorDx aims to lead in precision medicine by developing comprehensive clinical applications and research platforms. The company fosters collaborations with various stakeholders, including hospitals, research institutes, and third-party testing agencies, to create a complete industrial chain that facilitates the transformation of academic research into clinical products. Through its commitment to developing independent intellectual property and competitive clinical testing solutions, AnchorDx provides accurate and comprehensive services to patients, healthcare providers, and medical institutions.

Delfi Diagnostics, Inc. is a biotechnology company based in Baltimore, Maryland, focused on the early detection of cancer through innovative blood tests. Founded in 2018, the company employs artificial intelligence and genome sequencing to identify unique patterns of DNA fragmentation in the blood, enabling the detection of previously unrecognized cancer-associated cell-free DNA fragments. By utilizing machine learning, Delfi Diagnostics aims to develop high-precision, non-invasive blood tests that allow healthcare professionals to detect cancer at its most curable stage, thereby facilitating timely and effective treatment options for patients.

CoreMap, Inc. is a medical technology company based in Winooski, Vermont, focused on developing advanced diagnostic solutions for electrophysiologists treating atrial fibrillation. Incorporated in 2016, the company offers a micro-electrode solution that allows for sequential mapping of tissue properties, addressing significant challenges in the treatment of atrial fibrillation, such as poor spatial resolution and inadequate sample density. Additionally, CoreMap's ultra-high resolution electrodes provide detailed insights into cardiac activation, even during episodes of fibrillation. By enhancing the diagnostic capabilities of electrophysiologists, CoreMap aims to improve patient outcomes in the management of this complex condition.

MobileODT develops optical diagnostic devices and software for early cancer detection, enabling health care providers to perform visual examinations with portable, internet-connected tools. The Enhanced Visual Assessment system includes the FDA-cleared EVA COLPO portable colposcope and accompanying software to securely store and manage patient data via HIPAA-compliant cloud services such as EVA SANE, and a digital visualization tool for gynecologic exams, EVA WELL. The company also offers a portfolio of aids for screening, including a mobile app for Android that enables remote image capture and patient information tracking, an online portal for collaboration and reporting, and cloud storage solutions for documented patient data. Founded in 2012 and based in Tel Aviv with an additional location in New York, MobileODT aims to extend expert-level diagnostic capabilities to diverse healthcare settings and geographies, including applications in cervical cancer screening and other visual-based diagnostics.

Perfuse Therapeutics is a biotechnology company focused on developing therapies for eye diseases. It pursues a novel mechanism to improve retinal perfusion, with glaucoma as the initial focus. The company aims to protect and improve vision by slowing disease progression and reducing vascular-related damage in glaucoma, non-proliferative diabetic retinopathy, and retinal vein occlusion, enabling clinicians to preserve sight for affected patients.

BiomX develops bacteriophage-based therapies targeting bacteria linked to skin conditions and chronic diseases such as inflammatory bowel disease, liver disorders, and cancer. It collaborates with renowned institutions for research and development, aiming to create innovative microbiome therapeutics.

Health Catalyst is a technology company that specializes in data and analytics solutions for healthcare organizations. The company offers a platform that organizes, normalizes, and links health-related data from various systems, making it accessible and searchable for all users, including those without technical expertise. Health Catalyst operates through two main segments: the Technology segment, which generates the majority of its revenue through cloud-based subscriptions, time-based licenses, and maintenance fees for its data platforms and analytics applications; and the Professional Services segment, which provides a range of services including analytics, implementation, strategic advisory, and outsourcing to help clients optimize their use of the technology. By integrating and analyzing healthcare data, Health Catalyst aims to enhance decision-making and improve outcomes in the healthcare sector.

Health Catalyst is a technology company that specializes in data and analytics solutions for healthcare organizations. The company offers a platform that organizes, normalizes, and links health-related data from various systems, making it accessible and searchable for all users, including those without technical expertise. Health Catalyst operates through two main segments: the Technology segment, which generates the majority of its revenue through cloud-based subscriptions, time-based licenses, and maintenance fees for its data platforms and analytics applications; and the Professional Services segment, which provides a range of services including analytics, implementation, strategic advisory, and outsourcing to help clients optimize their use of the technology. By integrating and analyzing healthcare data, Health Catalyst aims to enhance decision-making and improve outcomes in the healthcare sector.

Alphamab Oncology is a clinical-stage biopharmaceutical company dedicated to the research, development, manufacture, and commercialization of innovative oncology biologics. Its pipeline includes bispecific monoclonal antibodies targeting immune checkpoints like PD-L1/CTLA-4 (KN046), next-generation anti-HER2 antibodies (KN026), CTLA-4 immunosuppressant fusion proteins (KN019), and injectable PD-L1 inhibitors for various cancer types (KN035). Founded in 2008, the company is headquartered in Suzhou, China.

SmartZyme Biopharma is a medical technology company focused on enhancing continuous glucose monitoring (CGM) for individuals with diabetes. It specializes in integrating its next-generation glucose-sensing enzyme into CGM devices, aiming to improve performance, safety, and user experience. Unlike traditional methods, SmartZyme's enzyme eliminates the need for signal mediators, reducing manufacturing costs; minimizes hypoglycemic errors, ensuring superior safety; and eliminates fingersticks, enhancing quality of life. The company is backed by OrbiMed, a leading healthcare investment firm.

Asian Institute of Medical Sciences is a 425-bed super-specialty hospital in Delhi NCR, India, dedicated to providing accessible and affordable healthcare services. Accredited by NABH and NABL, it offers comprehensive multi-specialty tertiary care through its 14 centers of excellence, covering cancer, heart, neurology, urology, renal diseases, bone and joint care, advanced imaging, gastroenterology, mother and child care, bariatric surgery, aesthetic medicine, and IVF.

MobileODT develops optical diagnostic devices and software for early cancer detection, enabling health care providers to perform visual examinations with portable, internet-connected tools. The Enhanced Visual Assessment system includes the FDA-cleared EVA COLPO portable colposcope and accompanying software to securely store and manage patient data via HIPAA-compliant cloud services such as EVA SANE, and a digital visualization tool for gynecologic exams, EVA WELL. The company also offers a portfolio of aids for screening, including a mobile app for Android that enables remote image capture and patient information tracking, an online portal for collaboration and reporting, and cloud storage solutions for documented patient data. Founded in 2012 and based in Tel Aviv with an additional location in New York, MobileODT aims to extend expert-level diagnostic capabilities to diverse healthcare settings and geographies, including applications in cervical cancer screening and other visual-based diagnostics.

BiomX develops bacteriophage-based therapies targeting bacteria linked to skin conditions and chronic diseases such as inflammatory bowel disease, liver disorders, and cancer. It collaborates with renowned institutions for research and development, aiming to create innovative microbiome therapeutics.

Guardant Health is a precision oncology company specializing in blood tests and analytics. It provides liquid biopsy tests like Guardant360 for advanced cancer detection, GuardantOMNI for broader gene panels, LUNAR-1 for minimal residual disease detection, and LUNAR-2 for early cancer detection. The company also offers development services to biopharmaceutical companies.

Suraksha Diagnostics is a diagnostic services company founded in 1992 in Kolkata as Suraksha Diagnostics and Eye Centre. It was among the first centers to offer pathology and radiology under one roof, delivering integrated testing and medical consultation. The company rapidly expanded, opening a second center in Siliguri within three years, the largest facility in the region, serving North Bengal and neighboring states. It has since grown across West Bengal, Bihar, Assam, Meghalaya, and Delhi NCR, building a network that includes a flagship central reference laboratory, satellite laboratories, and diagnostic centers with sample collection points to broaden access to pathology and radiology services for patients and clinicians.

Ornim, Inc. is a biomedical technology company specializing in the development and distribution of non-invasive medical monitoring tools for measuring blood flow and oxygen saturation in patients. Founded in 2004 and based in Santa Clarita, California, with a research and development subsidiary in Israel, Ornim has created innovative products such as the CerOx and c-FLOW monitors. These devices utilize patented UTLight technology, which combines light and ultrasound to deliver real-time, continuous measurements of cerebral blood flow and oxygen saturation. The CerOx monitor is unique in the market for its ability to measure both parameters simultaneously, while the c-FLOW focuses solely on cerebral blood flow. Ornim's solutions are designed to enhance individualized patient care by providing critical insights into blood flow variations, thereby enabling informed clinical interventions. The company holds numerous patents, reflecting its commitment to overcoming the limitations of existing monitoring technologies, and aims to improve treatment outcomes and reduce healthcare costs through its innovative monitoring solutions.

Response Biomedical Corp. is a Vancouver-based company that specializes in the research, development, commercialization, and distribution of diagnostic technologies. The company focuses on rapid on-site diagnostic tests for medical central-lab testing, point of care (POC) testing, and environmental testing markets. Its primary product is the RAMP system, a portable fluorescence immunoassay-based diagnostic platform that delivers laboratory-quality results quickly and conveniently through various formats, including hand-held devices and single-use test cartridges. Response Biomedical's tests are designed for early detection of conditions such as heart attacks, congestive heart failure, and influenza, as well as environmental threats like the West Nile Virus and biodefense applications for detecting agents such as anthrax and ricin. The company distributes its products globally, targeting markets in the United States, Asia, Latin and South America, Europe, the Middle East, and Canada. Founded in 1980, Response Biomedical is committed to improving patient management in acute care settings through efficient and rapid diagnostic solutions.

Founded in 2008, Nucleix Ltd. specializes in developing non-invasive molecular diagnostic tests for early cancer detection. Its proprietary tests, Bladder EpiCheck and Lung EpiCheck, identify subtle methylation changes in urine and blood samples respectively.

Guardant Health is a precision oncology company specializing in blood tests and analytics. It provides liquid biopsy tests like Guardant360 for advanced cancer detection, GuardantOMNI for broader gene panels, LUNAR-1 for minimal residual disease detection, and LUNAR-2 for early cancer detection. The company also offers development services to biopharmaceutical companies.

Eurolife Healthcare is a manufacturer and distributor of a diverse array of healthcare formulations tailored for various medical applications. The company specializes in producing generic pharmaceutical products, including intravenous infusions, ophthalmic solutions, sterilized water for injections, tablets, capsules, ointments, creams, and other formulations. Eurolife Healthcare emphasizes high-quality and sterile packaging to ensure that healthcare providers can effectively meet medical supply demands. Its product offerings extend to systems such as the eurohead infusion system, classic infusion therapy, and specialized solutions like Lifeflow and Germkill, designed to address specific therapeutic needs in the healthcare sector.

SmartZyme Biopharma is a medical technology company focused on enhancing continuous glucose monitoring (CGM) for individuals with diabetes. It specializes in integrating its next-generation glucose-sensing enzyme into CGM devices, aiming to improve performance, safety, and user experience. Unlike traditional methods, SmartZyme's enzyme eliminates the need for signal mediators, reducing manufacturing costs; minimizes hypoglycemic errors, ensuring superior safety; and eliminates fingersticks, enhancing quality of life. The company is backed by OrbiMed, a leading healthcare investment firm.

Invitae is a genetic information company focused on integrating genetic insights into everyday medical practice to enhance healthcare quality for a large population. The company specializes in genetic diagnostics for hereditary disorders, offering a comprehensive service that consolidates multiple genetic tests into a single platform. Invitae's offerings include assessments for genes linked to hereditary cancer, neurological disorders, cardiovascular conditions, pediatric issues, metabolic disorders, and other hereditary ailments. By providing high-quality testing with quicker turnaround times and competitive pricing, Invitae aims to make genetic testing more accessible and effective for patients and healthcare providers alike.

Rapid Pathogen Screening, Inc., established in 2004 and headquartered in Sarasota, Florida, is a biotechnology company specializing in the development, manufacture, and marketing of point-of-care diagnostic tests. The company's innovative technology platform enables the creation of cost-effective tests for rapid identification of infectious diseases and inflammatory conditions. Notable products include AdenoPlus, a test for adenoviral conjunctivitis, and InflammaDry, a dry eye test. These tests are designed to be easily administered by clinicians with minimal training and equipment. Additionally, through U.S. government contracts, the company is developing tests for bio-terrorism agents and chemical nerve agent blood toxins. Rapid Pathogen Screening's products are distributed globally through various healthcare providers and distributors.

Whale is a manufacturer of imaging devices, including multi-planar surgical imaging and portable diagnostic ultrasound products. It develops portable ultrasound systems and surgical imaging equipment, employing proprietary technologies and advanced manufacturing methods to produce safe devices that enable surgeons to perform procedures with speed and ease.

Ornim, Inc. is a biomedical technology company specializing in the development and distribution of non-invasive medical monitoring tools for measuring blood flow and oxygen saturation in patients. Founded in 2004 and based in Santa Clarita, California, with a research and development subsidiary in Israel, Ornim has created innovative products such as the CerOx and c-FLOW monitors. These devices utilize patented UTLight technology, which combines light and ultrasound to deliver real-time, continuous measurements of cerebral blood flow and oxygen saturation. The CerOx monitor is unique in the market for its ability to measure both parameters simultaneously, while the c-FLOW focuses solely on cerebral blood flow. Ornim's solutions are designed to enhance individualized patient care by providing critical insights into blood flow variations, thereby enabling informed clinical interventions. The company holds numerous patents, reflecting its commitment to overcoming the limitations of existing monitoring technologies, and aims to improve treatment outcomes and reduce healthcare costs through its innovative monitoring solutions.

RedHill Biopharma Ltd. is a specialty biopharmaceutical company headquartered in Tel Aviv, Israel, with a primary focus on gastrointestinal and infectious diseases. The company develops and promotes several gastrointestinal drugs, including Movantik for opioid-induced constipation, Talicia for treating Helicobacter pylori infection, and Aemcolo for travelers' diarrhea. RedHill's late-stage clinical development programs include RHB-204, aimed at treating pulmonary nontuberculous mycobacteria infections; RHB-104 for Crohn's disease; and RHB-102 (Bekinda), which has shown promise in Phase 3 studies for acute gastroenteritis and gastritis. Additionally, the company is advancing RHB-107, a serine protease inhibitor for cancer and inflammatory gastrointestinal diseases, and opaganib, which is being investigated for various conditions, including COVID-19. Founded in 2009, RedHill Biopharma is committed to innovation in the management of gastrointestinal and infectious diseases.

Amoy Diagnostics Co., Ltd. is a research and development focused diagnostic company that specializes in molecular diagnostics for oncology precision medicine. The company offers a portfolio of assays built on PCR, next‑generation sequencing, fluorescence in situ hybridization, and immunohistochemistry platforms. Its product range includes single‑gene testing kits, multi‑gene panels, NGS panels, and NGS analytical systems.

Singulex develops and commercializes single molecule counting technology for clinical diagnostics and scientific discovery. Its flagship product, the Sgx Clarity System, enables ultra-sensitive detection of biomarkers down to femtograms/mL, aiding in cardiovascular health management and personalized wellness programs. Singulex serves pharmaceutical R&D labs, clinical research organizations, and academic institutions worldwide.

Founded in 2008, Treato Ltd. operates Treato, a platform that aggregates and analyzes patient experiences from online health discussions. It provides insights for patients, healthcare professionals, pharmaceutical companies, and other organizations to understand patient needs and attitudes.

Whale Imaging Inc., established in 1998, is a Massachusetts-based manufacturer of medical devices specializing in surgical imaging systems and ultrasound equipment. The company's product portfolio includes G-Arm Products like the G-Arm B6 Duo and G-Arm GXi 2, as well as portable ultrasound systems such as the Lambda P9 and Sigma P5. In addition to manufacturing, Whale Imaging offers training services, preventative maintenance, and customer support for its products. The company's headquarters are in Waltham, Massachusetts, with research and development facilities located in Boston.

Ornim, Inc. is a biomedical technology company specializing in the development and distribution of non-invasive medical monitoring tools for measuring blood flow and oxygen saturation in patients. Founded in 2004 and based in Santa Clarita, California, with a research and development subsidiary in Israel, Ornim has created innovative products such as the CerOx and c-FLOW monitors. These devices utilize patented UTLight technology, which combines light and ultrasound to deliver real-time, continuous measurements of cerebral blood flow and oxygen saturation. The CerOx monitor is unique in the market for its ability to measure both parameters simultaneously, while the c-FLOW focuses solely on cerebral blood flow. Ornim's solutions are designed to enhance individualized patient care by providing critical insights into blood flow variations, thereby enabling informed clinical interventions. The company holds numerous patents, reflecting its commitment to overcoming the limitations of existing monitoring technologies, and aims to improve treatment outcomes and reduce healthcare costs through its innovative monitoring solutions.

Good Start Genetics, Inc. is a molecular diagnostics company based in Cambridge, Massachusetts, founded in 2007. It specializes in genetic screening for inherited diseases, aiming to transform reproductive medicine by providing actionable information to physicians and patients. The company offers a range of services, including EmbryVu, a preimplantation genetic screening test designed to enhance in vitro fertilization outcomes by identifying suitable embryos for implantation. Additionally, Good Start Genetics provides a comprehensive array of genetic carrier screening tests through its GoodStart Select program, utilizing advanced next-generation DNA sequencing technology along with other established genetic screening methods. This focus on high carrier detection rates and commitment to customer care and genetic counseling positions the company as a leader in the field of pre-pregnancy genetic testing and diagnostics. As of August 2017, Good Start Genetics operates as a subsidiary of Invitae Corporation.

Singulex develops and commercializes single molecule counting technology for clinical diagnostics and scientific discovery. Its flagship product, the Sgx Clarity System, enables ultra-sensitive detection of biomarkers down to femtograms/mL, aiding in cardiovascular health management and personalized wellness programs. Singulex serves pharmaceutical R&D labs, clinical research organizations, and academic institutions worldwide.

Kerala Institute of Medical Sciences is a multi-specialty tertiary care hospital network delivering care from primary to quaternary levels through a team of specialists and advanced technology. Founded in 2002 and based in Thiruvananthapuram, India, it emphasizes quality and safe patient care and operates educational institutions that offer nursing training, post-graduate programs including DNB, fellowships and international courses, as well as a College of Nursing, Institute of Skill Development and a Paramedical Institute. The network provides comprehensive medical services, supports research and education, and runs health check programs, emergency services and specialized clinics across its facilities.

Roka Bioscience specializes in the development of rapid and accurate molecular assays and instrument systems aimed at the food safety industry. The company's latest innovation, the Atlas System, introduces advanced molecular rapid pathogen testing, which enhances laboratory efficiency through automation and user-friendly design. By focusing on innovative testing solutions, Roka Bioscience aims to assist food manufacturers in minimizing risks, safeguarding their brands, and addressing the growing demands for testing in the sector.

Roka Bioscience specializes in the development of rapid and accurate molecular assays and instrument systems aimed at the food safety industry. The company's latest innovation, the Atlas System, introduces advanced molecular rapid pathogen testing, which enhances laboratory efficiency through automation and user-friendly design. By focusing on innovative testing solutions, Roka Bioscience aims to assist food manufacturers in minimizing risks, safeguarding their brands, and addressing the growing demands for testing in the sector.

Good Start Genetics, Inc. is a molecular diagnostics company based in Cambridge, Massachusetts, founded in 2007. It specializes in genetic screening for inherited diseases, aiming to transform reproductive medicine by providing actionable information to physicians and patients. The company offers a range of services, including EmbryVu, a preimplantation genetic screening test designed to enhance in vitro fertilization outcomes by identifying suitable embryos for implantation. Additionally, Good Start Genetics provides a comprehensive array of genetic carrier screening tests through its GoodStart Select program, utilizing advanced next-generation DNA sequencing technology along with other established genetic screening methods. This focus on high carrier detection rates and commitment to customer care and genetic counseling positions the company as a leader in the field of pre-pregnancy genetic testing and diagnostics. As of August 2017, Good Start Genetics operates as a subsidiary of Invitae Corporation.

SuperDimension is a privately-held medical device company that specializes in developing and marketing minimally-invasive pulmonology devices aimed at diagnosing and treating distal lung disease. The company’s main product, the i·Logic System, includes both capital equipment and disposable tools designed to enhance traditional bronchoscopy techniques. These innovations allow physicians to access peripheral lung lesions and mediastinal lymph nodes, facilitating the diagnosis of previously inaccessible lung conditions at earlier stages when they may be more treatable. SuperDimension is committed to becoming a leader in the field of distal lung disease diagnosis and treatment, addressing a significant market of over 8 million patients.

SuperDimension is a privately-held medical device company that specializes in developing and marketing minimally-invasive pulmonology devices aimed at diagnosing and treating distal lung disease. The company’s main product, the i·Logic System, includes both capital equipment and disposable tools designed to enhance traditional bronchoscopy techniques. These innovations allow physicians to access peripheral lung lesions and mediastinal lymph nodes, facilitating the diagnosis of previously inaccessible lung conditions at earlier stages when they may be more treatable. SuperDimension is committed to becoming a leader in the field of distal lung disease diagnosis and treatment, addressing a significant market of over 8 million patients.

Singulex develops and commercializes single molecule counting technology for clinical diagnostics and scientific discovery. Its flagship product, the Sgx Clarity System, enables ultra-sensitive detection of biomarkers down to femtograms/mL, aiding in cardiovascular health management and personalized wellness programs. Singulex serves pharmaceutical R&D labs, clinical research organizations, and academic institutions worldwide.

Gelesis is a biotechnology company developing therapies to treat obesity and other gastrointestinal-related chronic diseases. It specializes in mechanobiology technology, with its lead product PLENITY being an orally-administered, non-stimulant aid for weight management.

Singulex develops and commercializes single molecule counting technology for clinical diagnostics and scientific discovery. Its flagship product, the Sgx Clarity System, enables ultra-sensitive detection of biomarkers down to femtograms/mL, aiding in cardiovascular health management and personalized wellness programs. Singulex serves pharmaceutical R&D labs, clinical research organizations, and academic institutions worldwide.

Amnis manufactures and supplies flow cytometry products and services. Their technology is used in research and clinical studies with biomedical and therapeutic applications, including investigating the role of the body’s immune system in fighting cancer, diagnosing leukemia and lymphoma, and detecting minimal residual disease in organ transplant patients.

SuperDimension is a privately-held medical device company that specializes in developing and marketing minimally-invasive pulmonology devices aimed at diagnosing and treating distal lung disease. The company’s main product, the i·Logic System, includes both capital equipment and disposable tools designed to enhance traditional bronchoscopy techniques. These innovations allow physicians to access peripheral lung lesions and mediastinal lymph nodes, facilitating the diagnosis of previously inaccessible lung conditions at earlier stages when they may be more treatable. SuperDimension is committed to becoming a leader in the field of distal lung disease diagnosis and treatment, addressing a significant market of over 8 million patients.

Amnis manufactures and supplies flow cytometry products and services. Their technology is used in research and clinical studies with biomedical and therapeutic applications, including investigating the role of the body’s immune system in fighting cancer, diagnosing leukemia and lymphoma, and detecting minimal residual disease in organ transplant patients.

Molecular Staging Inc., a life sciences tool company, specializes in developing technologies for the detection and measurement of proteins and nucleic acids. Its offerings include protein microarrays for proteomics research, whole-genome amplification tools to overcome limited DNA sample constraints, and multiplexed diagnostics for enhanced disease detection. These products cater to applications in genomics, pharmacogenomics, and diagnostics.